Ascletis Pharma Inc.

Investors

Financials & Filing

2025

2024

2023

2022

2021

2020

2019

2018

Voluntary Announcement - Completion of Bridging Study of ASC18
2020-08-20
Voluntary Announcement - First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, A Subcutaneously Administered PD-L1 Antibody
2020-08-17
Notice of Board Meeting
2020-08-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2020
2020-08-05
Voluntary Announcement - Approval for Marketing All-oral HCV Treatment
2020-07-31
Voluntary Announcement - Bridging Study in China Completed for NASH Drug Candidate ASC40
2020-07-20
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020
2020-07-03
List of Directors and Their Role and Function
2020-06-30
Resignation of Independent Non-Executive Director; Change in Composition of the Board Committees
2020-06-30
Voluntary Announcement - ASC40 (TVB2640) Significantly Reduced Liver Fat with a 61% Responder Rate in Phase 2 NASH Trial
2020-06-17

4

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1